Why the study?
Does simvastatin reduce serologic markers of vascular disease activity in hypercholesterolemic patients with coronary artery disease?
Population
13 hypercholesterolemic patients with established coronary artery disease who remained hypercholesterolemic…
Comparison
Simvastatin 20-40 mg daily for 14 weeks vs Pretreatment values (baseline)
Design
Cohort
Follow-up
14 weeks
Authors
Loading...
Supports pleiotropic anti-inflammatory effects in CAD; hypothesis-generating pending randomized outcome trials.
Does simvastatin reduce serologic markers of vascular disease activity in hypercholesterolemic patients with coronary artery disease?
Simvastatin reduces inflammatory and plaque-destabilizing biomarkers like MMP-9 and MCP-1 independent of lipid lowering, supporting pleiotropic benefits in coronary artery disease.
Koh et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: